Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025

Core Viewpoint - Monte Rosa Therapeutics is set to present clinical results from its Phase 1 SAD/MAD study of the VAV1-directed molecular glue degrader MRT-6160 and the Phase 1/2 study of MRT-2359 in MYC-driven solid tumors on March 20, 2025, alongside its financial results for Q4 and full year 2024 [1]. Group 1 - The company is a clinical-stage biotechnology firm focused on developing novel molecular glue degrader (MGD) medicines for serious diseases, including oncology and autoimmune conditions [3]. - Monte Rosa's QuEEN™ discovery engine utilizes AI-guided chemistry and structural biology to identify and design highly selective MGDs, enabling access to a diverse range of therapeutic targets [3]. - The company has established a global license agreement with Novartis for VAV1-directed molecular glue degraders and a strategic collaboration with Roche for developing MGDs against challenging targets in cancer and neurological diseases [3]. Group 2 - A conference call and webcast for the presentation will be available on the company's website, with an archived version accessible for 30 days post-presentation [2].